The company’s earnings were impacted by the voluntary recall of the Rejuvenate and ABG III modular-neck hip stems, which related charges totaling $230 million. Another $40 million charge was recorded for two additional regulatory matters.
The company reported an increase in neurotechnology and spine net sales, which reached $397 million during the first quarter. The reconstructive net sales increased 1.2 percent to $969 million in the first quarter.
In March, the company completed its acquisition of Trauson Holdings, which will expand the company’s presence in the Chinese orthopedic market.
More Articles on Orthopedic Devices:
Zimmer Reports Flat Q1 Sales, Spine Plummets 10%
5 Recent Orthopedic Device & Procedure Launches
K2M Releases VESUVIUS Putty Osteobiologic Product
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
